The new federal administration of President Barack Obama is putting together the team it hopes will deliver a major health care reform package, following the setback of former US Senator Tom Daschle's failed nomination as Secretary of Health and Human Services (Marketletter February 9) over tax evasion claims. The new choice of HHS Secretary is Governor Kathleen Sebelius (Democrat, Kansas), who was widely rumored to be the then presidential candidate's most favored female choice for running mate shortly before the Democratic convention last year.
The White House Office for Health Reform, in an echo to a position once held by previous Democratic Pres Bill Clinton's wife in 1993, will be run by Nancy-Ann De-Parle, who then assisted Hillary Clinton (the new Secretary of State), the then architect of health care reform.
A summit at the White House to discuss the President's goals for change is due to be held in the first week of March, gathering 120 politicians, lobbyists and activists. During the election campaign which ended last November, Pres Obama's agenda appeared to focus on a government-subsidized health insurance plan that would compete against private providers in a government-controlled market place. Critics claim that such a scheme will fail to offer Americans any choice, because private operators will be "crowded out."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze